Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Blueprint Medicines Corp (BPMC)
Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,004,131
  • Shares Outstanding, K 60,665
  • Annual Sales, $ 204,040 K
  • Annual Income, $ -557,520 K
  • 60-Month Beta 0.74
  • Price/Sales 14.68
  • Price/Cash Flow N/A
  • Price/Book 9.86
Trade BPMC with:

Options Overview Details

View History
  • Implied Volatility 43.22% ( -1.66%)
  • Historical Volatility 32.59%
  • IV Percentile 9%
  • IV Rank 17.94%
  • IV High 76.29% on 10/12/22
  • IV Low 35.99% on 06/07/23
  • Put/Call Vol Ratio 0.51
  • Today's Volume 127
  • Volume Avg (30-Day) 233
  • Put/Call OI Ratio 2.19
  • Today's Open Interest 13,673
  • Open Int (30-Day) 12,226

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -2.40
  • Number of Estimates 11
  • High Estimate -2.21
  • Low Estimate -2.69
  • Prior Year -2.23
  • Growth Rate Est. (year over year) -7.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.52 +2.06%
on 08/29/23
54.98 -9.93%
on 09/11/23
+0.18 (+0.36%)
since 08/22/23
3-Month
46.51 +6.47%
on 08/08/23
68.00 -27.18%
on 07/31/23
-14.56 (-22.72%)
since 06/22/23
52-Week
37.82 +30.94%
on 02/24/23
68.63 -27.84%
on 10/04/22
-17.58 (-26.20%)
since 09/22/22

Most Recent Stories

More News
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint...

BPMC : 49.52 (+0.30%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint...

BPMC : 49.52 (+0.30%)
Why Shares of Blueprint Medicines Are Falling Wednesday

The company had generally improved earnings.

BPMC : 49.52 (+0.30%)
Blueprint Medicines: Q2 Earnings Snapshot

Blueprint Medicines: Q2 Earnings Snapshot

BPMC : 49.52 (+0.30%)
Blueprint Medicines Reports Second Quarter 2023 Results

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended...

BPMC : 49.52 (+0.30%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint...

BPMC : 49.52 (+0.30%)
What Will AbbVie Buy Next?

Two mid-cap drugmakers stand out as logical targets for AbbVie.

AGN.AX : 0.410 (+2.50%)
ABBV : 152.74 (-0.45%)
BPMC : 49.52 (+0.30%)
KRYS : 115.14 (-3.06%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective June 1, 2023, the Compensation Committee of Blueprint...

BPMC : 49.52 (+0.30%)
This Biotech Could Soon Go Parabolic, But Should You Buy It?

Its situation is neither as good nor as bad as it might seem at first glance.

BPMC : 49.52 (+0.30%)
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced clinical data for multiple programs across its precision therapy portfolio at...

BPMC : 49.52 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

See More

Key Turning Points

3rd Resistance Point 51.88
2nd Resistance Point 51.03
1st Resistance Point 50.28
Last Price 49.52
1st Support Level 48.68
2nd Support Level 47.83
3rd Support Level 47.08

See More

52-Week High 68.63
Fibonacci 61.8% 56.86
Fibonacci 50% 53.22
Fibonacci 38.2% 49.59
Last Price 49.52
52-Week Low 37.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar